Table 3.

Use of SGLT2i in patients DKD: impact of eGFR

Drug		EMA (as of May 2019) [47]	FDA (as of May 2019) [44]	ADA-EASD 2018 [50]	ESC 2016 [49]	EURECA-m and DIABESITY 2019 [51]	CREDENCE-based likely future suggestions
SGLT2i	Canagliflozin	Should not be initiated when eGFR <60 Should be discontinued at GFR persistently <45	Contraindicated if  eGFR <30	Authorized eGFR varies with agent and local health authority	No mention	SGLT2i were used in EMPA-REG OUTCOME and CANVAS up to eGFR 30, but current indication is >45 for empagliflozin and canagliflozin and >60 for dapagliflozin’	Use at any GFR not yet on dialysis for kidney and cardiovascular protection
	Dapagliflozin		Should not be initiated when eGFR <60 Contraindicated if eGFR <30				?
	Empagliflozin		Should not be initiated when eGFR <45 Contraindicated if eGFR <30				?

CREDENCE based likely future suggestions reflect the author’s views regarding potential future guidelines of EMA indications based on the results of the CREDENCE trial. These should be considered hypothetical and may not reflect the eventual decisions by these bodies. eGFR in mL/min/1.73 m². EMA, ADA-EASD, ESCEURECA-m and DIABESITY are ERA-EDTA working groups.